Printer Friendly

SEARLE DONATES $500,000 OF MAXAQUIN (LOMEFLOXACIN HCL) TO RUSSIAN FOUNDATION

 CHICAGO, Jan. 25 /PRNewswire/ -- Searle announced today the donation of Maxaquin(R) (lomefloxacin HCl) valued at $500,000 to the National Health Foundation of Russia.
 Maxaquin is Searle's once-a-day quinolone anti-infective indicated for the treatment of certain acute exacerbations of chronic bronchitis, upper and lower urinary tract infections (complicated and uncomplicated) and prophylaxis in transurethral surgery. The product will be dispensed at eight treatment facilities throughout Russia.
 "With drugs in continually short supply in Russia, a very strong need exists for modern anti-infectives such as Maxaquin," said Dr. Ronald Goode, corporate senior vice president and president, international operations. "Maxaquin will be especially useful in treating chronic bronchitis, a major health problem in Russia. This donation of Maxaquin to Russia exemplifies Searle's strong commitment to improving human health around the world, as evidenced in Searle's on- going social responsibility programs -- Patients In Need(R), Patient Promise(R), and Patients In the Know(R)."
 In conjunction with the donation, Searle has conducted a day-long symposium for physicians summarizing the clinical applications of Maxaquin.
 This is the second major product donation by Searle to Russia. In 1990, the company donated $500,000 of products from its cardiovascular, gastrointestinal, anti-infective and female contraceptive lines.
 Searle is a research-based pharmaceutical company that develops, manufacturers and markets prescription pharmaceuticals worldwide. It is a wholly owned subsidiary of Monsanto Company (NYSE: MTC).
 -0- 1/25/93
 /CONTACT: Jeffery Newton of Searle, 708-470-6280/
 (MTC)


CO: Searle ST: Illinois IN: MTC SU:

CK -- NY072 -- 8547 01/25/93 13:33 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 25, 1993
Words:252
Previous Article:SEARS, ROEBUCK & CO. ISSUES LIST OF STORE CLOSINGS
Next Article:NEW WARWICK MINING COMPANY SEEKS NATIONAL LABOR AGREEMENT
Topics:


Related Articles
FIRST ONE-TABLET, ONCE-A-DAY QUINOLONE FOR ALL INDICATIONS ENTERS $5.1 BILLION U.S. ANTI-INFECTIVE MARKET
SEARLE AND WYETH-AYERST TO CO-PROMOTE MAXAQUIN
SEARLE AND WYETH-AYERST CO-PROMOTE ONLY ONCE-A-DAY QUINOLONE ANTIBIOTIC
RUSSIA APPROVES FIST ONCE-A-DAY QUINOLONE FOR ANTI-INFECTIVE USE
SEARLE PROVIDES 500,000 UNITS OF MEDICINES FOR SOMALIA IN RELIEF EFFORT SPEARHEADED BY U.S. SEN. SIMON
SEARLE DONATES ANTI-INFECTIVE AGENT TO AID VICTIMS OF CHERNOBYL DISASTER
Searle, Unimed Reach Agreement On U.S. Marketing And Distribution Rights For Maxaquin
Maxaquin Now Indicated for Once-A-Day, 3-Day Treatment of Prevalent Urinary Tract Infection
Unimed Announces 96% Revenue Growth for First Half of 1998
Unimed Announces Third Consecutive Quarter of Double Digit Revenue Growth.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters